Ubiquitination and downregulation of ErbB2 and estrogen receptor-alpha by kinase inhibitor MP-412 in human breast cancer cells

Journal of Cellular Biochemistry

Volumn 112, Issue 9, 2011, Pages 2279-2286

  Suzuki, Tsuyoshi ^a   Fujii, Akihiro ^a   Ochi, Hiroshi ^a   Nakamura, Hideo ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

ErbB2; Estrogen receptor alpha; Hsp90; MP 412; Ubiquitin

Indexed keywords

CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; HEAT SHOCK PROTEIN 70; MP 412; PHOSPHOTRANSFERASE INHIBITOR; RAF PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER THERAPY; CELL LYSATE; COVALENT BOND; DRUG DESIGN; DRUG INHIBITION; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RECEPTOR DOWN REGULATION; UBIQUITINATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME ACTIVATION; ESTROGEN RECEPTOR ALPHA; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PIPERAZINES; PROTEIN BIOSYNTHESIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; STRESS, PHYSIOLOGICAL; UBIQUITINATION;

EID: 84860390870     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23147     Document Type: Article

References (31)

1. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M,. 2005. Phase I pharmacokinetic and pharmacodynamic study of 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23: 4152-4161. (Pubitemid 46211321)
2. Brandt GEL, Blagg BSJ,. 2009. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Curr Top Med Chem 9: 1447-1461.
3. Bulletin Board (No authors listed). 2010. Breast cancer drug approved for new indication. Womens Health 6: 173.
4. Citri A, Alroy I, Lavi S, Rubin C, Xu W, Grammatikakis N, Patterson C, Neckers L, Fry D, Yarden Y,. 2002. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: Implications for cancer therapy. EMBO J 21: 2407-2417. (Pubitemid 34546713)
5. Ehrlich ES, Wang T, Luo K, Xia Z, Niewiadomska AM, Martinez T, Xu W, Neckers L, Yu X,. 2009. Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. Proc Natl Acad Sci USA 106: 20330-20335.
6. Fan M, Bigsby RM, Nephew KP,. 2003. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-α and essential for the antiproliferative activity of ICI 182,780 in ERα-positive breast cancer cells. Mol Endocrinol 17: 356-365. (Pubitemid 36315630)
7. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM,. 1998. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 95: 12022-12027. (Pubitemid 28460532)
8. Fan M, Park A, Nephew KP,. 2005. CHIP (carboxy terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-α. Mol Endocrinol 19: 2901-2914. (Pubitemid 41697710)
9. Fujino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K,. 2003. Histon deacetylase inhibitor LAQ824 down-regulates Her2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2: 971-984.
10. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J,. 2006. Gene expression signature-based chemical genomic prediction identifies a novel class of Hsp90 pathway modulators. Cancer Cell 10: 321-330. (Pubitemid 44512193)
11. Jeong JH, An JY, Kwon YT, Li LY, Lee YJ,. 2008. Quercetin-induced ubiquitination and down-regulation of Her2/neu. J Cell Biochem 105: 585-595.
12. Jung Y, Xu W, Kim H, Ha N, Neckers L,. 2007. Curcumin-induced degradation of ErbB2: A role for the E3 ubiquitin ligase CHIP and the Michael reaction acceptor activity of curcumin. Biochim Biophys Acta 1773: 383-390. (Pubitemid 46275067)
13. Kamal A, Boehm M, Burrows FJ,. 2004. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 10: 283-290. (Pubitemid 38725896)
14. Kurokawa H, Lenferink AEG, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL,., 2000. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60: 5887-5894.
15. Lam PB, Burga LN, Wu BP, Hofstatter EW, Lu KP, Wulf GM,. 2008. Prolyl isomerease Pin I is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Mol Cancer 7: 91.
16. Mimnaugh EG, Chavany C, Neckers L,. 1996. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271: 22796-22801. (Pubitemid 26304727)
17. Morimoto RI,. 2002. Dynamic remodeling of transcription complexes by molecular chaperones. Cell 110: 281-284.
18. Mukhopadhyay D, Riezman H,. 2007. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 315: 201-205. (Pubitemid 46166358)
19. Parkin DM, Bray F, Ferlay J, Pisani P,. 2005. Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108. (Pubitemid 40372904)
20. Sato K, Rajendra E, Ohta T,. 2008. The UPS: A promising target for breast cancer treatment. BMC Biochem 9: S2.
21. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. 1987. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177-182. (Pubitemid 17231334)
22. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L,. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresss HER2. N Engl J Med 344: 783-792. (Pubitemid 32222155)
23. Sreeramulus S, Gande SL, Gobel M, Schwalbe H,. 2009. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew Chem Int Ed 48: 5853-5855.
24. Suzuki T, Fujii A, Ohya J, Amano Y, Kitano Y, Abe D, Nakamura H,. 2007. Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor. Cancer Sci 98: 1977-1984. (Pubitemid 350002206)
25. Suzuki T, Fujii A, Ohya J, Nakamura H, Fujita F, Koike M, Fujita M,. 2009. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models. Cancer Sci 100: 1526-1531.
26. Westerheide SD, Bosman JD, Mbadugha BNA, Kawahara TLA, Matsumoto G, Kim S, Gu W, Devlin JP, Silverman RB, Morimoto RI,. 2004. Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 279: 56053-56060. (Pubitemid 40066613)
27. Xu W, Mimnaugh E, Rosser MFN, Nicchitta C, Marcu M, Yarden Y, Neckers L,. 2001. Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276: 3702-3708.
28. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L,. 2002. Chaeprone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/neu. Proc Natl Acad Sci USA 99: 12847-12852.
29. Yang H, Chen D, Cui QC, Yuan X, Dou QP,. 2006. Celastrol, a triterpene extracted from the Chinese "Thunder of god vine", is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66: 4758-4765.
30. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan C-G, Sun D,. 2008. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 7: 162-170.
31. Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, Safran H, DiPetrillo TA, Wazer DE, Band V,. 2003. ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 278: 13829-13837. (Pubitemid 36799921)